
- Facilitated leadership for low market-share Animal Health Business with strategic acquisition
- Position extension of human nutraceutical and serious immune modulator for Quality of Life Support in companion animals undergoing chemotherapy and radiation
- Quantum leap in sales and profitability with new Animal Health business strategy in Asia
- Protected European registration and reversed Asian trade barrier for US feed supplement
- Reversed profit decline for global Animal Health Business with COGS rationalization
- Reversed sales decline for global product with new formulations
- Reversed price decline for European product group
- Enhanced valuation of Global Animal Health business with competitive registrations
|
|